Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Southern California
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. To collect and analyze small cell lung cancer (SCLC) tumor DNA and ribonucleic acid (RNA) from 3 human patients before and after relapse to identify the molecular signatures of relapse.
OUTLINE:
Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any patient seen at Norris or County with histologically confirmed SCLC, with tissue in the Norris Cancer Center Tumor Repository
Patients must be undergoing or about to start first line treatment with cisplatin and etoposide
Patients may not have a second malignancy
Clareo Health | Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide
